Disease stage in Alzheimer disease and treatment effects of rivastigmine

Alzheimer Disease and Associated Disorders

Volumn 18, Issue 3, 2004, Pages 123-128

  Kurz, Alexander ^a   Farlow, Martin ^b   Quarg, Peter ^c   Spiegel, René ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INDIANA UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical trial; Rivastigmine

Indexed keywords

RIVASTIGMINE;

AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; URINARY TRACT INFECTION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PLACEBOS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 4444229993     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000127445.00442.a1     Document Type: Article

References (20)

1. Geula C, Greenberg BD, Mesulam MM. Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer disease does not emanate from amyloid. Brain Res. 1994;644:327-330.
2. Braak H, Griffing K, Braak E. Neuroanatomy of Alzheimer disease. Alzheimer Res. 1997;3:235-247.
3. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 73 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
5. Schneider A, Anand R, Farlow M. Systematic review of the efficacy of rivastigmine for patients with Alzheimer disease. Int J Geriatr Psychopharmacol. 1998;1(suppl):26-34.
6. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer disease: international randomised controlled trial. Br Med J. 1999;318:633-638.
7. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:705-712.
8. Potkin SG, Anand R, Hartman R, et al. Impact of Alzheimer disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:713-720.
9. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
10. Mohs RC, Rosen WG, Davis KL. The Alzheimer Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19:448-450.
11. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer disease. Clin Ther. 1989;11:545-554.
12. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (ClBl): a clinician's global change rating scale in Alzheimer disease. Neurology. 1994;44:2315-2321.
13. Feldman H, Spiegel R, Quarg P. An evaluation of the effects of rivastigmine on daily function in Alzheimer's disease at different levels of cognitive impairment. Neurology. 2003;60(suppl 1):A142.
14. Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002;9:88-93.
15. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer disease resemble embryonic development: a study of molecular forms. Neurochem Int. 1992;21:381-396.
16. Siek GC, Katz LS, Fishman EB, et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry. 1990;27:573-580.
17. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs. 1999;12:307-323.
18. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord. 2003;15:79-87.
19. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51:737-744.
20. Shua-Haim JR, Smith JM, Amin S. Safety and tolerability of slow titration of rivastigmine in the treatment of patient's with Alzheimer disease. American Geriatrics Society, Annual Scientific Meeting: Caring for Older Adults. Innovations on Research and Practice. Chicago: American Geriatrics Society, 2001.